G6PC-deficient GSDIa mouse model: dose-dependent increases in hepatic G6Pase activity and fasting glucose
“In vivo pharmacology studies conducted in 2-week-old glucose-6-phosphatase, catalytic subunit 1 (G6PC) demonstrated that IV administration of DTX401 at dose levels of 5.0 × 1011 or 1.0 × 1013 gc/kg led to dose-dependent increases in hepatic G6Pase activity and fasting glucose levels.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Why that model
Disease mouse model available that mimics human GSDIa (hypoglycemia, growth retardation, hepatomegaly, nephromegaly)
“model is associated with high early mortality at weaning and mimics features of human GSDIa including hypoglycemia, growth retardation, hepatomegaly, and nephromegaly”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Reviewer's view of the efficacy data
Mouse disease-model data accepted as confirmatory mechanistic evidence of effectiveness
“These data provide confirmatory mechanistic evidence in support of the effectiveness of DTX401.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
WAS-deficient mice transplanted with WAS LVV-transduced murine Lin- BM cells: increased B cells, platelets, granulocytes; improved T, B and DC function